Ralf A. Hilger

4.2k total citations · 1 hit paper
83 papers, 3.2k citations indexed

About

Ralf A. Hilger is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ralf A. Hilger has authored 83 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 30 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ralf A. Hilger's work include Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (12 papers) and Melanoma and MAPK Pathways (8 papers). Ralf A. Hilger is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (12 papers) and Melanoma and MAPK Pathways (8 papers). Ralf A. Hilger collaborates with scholars based in Germany, United States and Switzerland. Ralf A. Hilger's co-authors include M. E. Scheulen, Dirk Strumberg, S. Seeber, Heike Richly, E. Brendel, Brian Schwartz, R. Voigtmann, D. Voliotis, N. Schleucher and Markus Faghih and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Ralf A. Hilger

81 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

2004 694 citations Dirk Strumberg, Heike Richly et al. profile →

Peers

Countries citing papers authored by Ralf A. Hilger

Since Specialization

Citations

This map shows the geographic impact of Ralf A. Hilger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf A. Hilger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf A. Hilger more than expected).

Fields of papers citing papers by Ralf A. Hilger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralf A. Hilger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf A. Hilger. The network helps show where Ralf A. Hilger may publish in the future.

Co-authorship network of co-authors of Ralf A. Hilger

This figure shows the co-authorship network connecting the top 25 collaborators of Ralf A. Hilger. A scholar is included among the top collaborators of Ralf A. Hilger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf A. Hilger. Ralf A. Hilger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach 2021 ·British Journal of Clinical Pharmacology ·Stephan Schaller, Frederico Severino Martins, (unknown), (unknown), Joachim Baumgart, Ralf A. Hilger, Dietrich W. Beelen, Claudia Hemmelmann, Arne Ring	4
2	Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells 2020 ·Molecular Oncology ·(unknown), (unknown), Diana Mendus, Ralf A. Hilger, Trudy G. Oliver, Kim L. Mercer, Björn-Oliver Gohlke, Kati Erdmann, Dieter Niederacher, Hans Neubauer, Paul Buderath, Pauline Wimberger, Jan Dominik Kuhlmann, Jürgen Thomale	7
3	The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib 2020 ·Gynecologic Oncology ·(unknown), Daniel Martin Klotz, (unknown), Ralf A. Hilger, Konrad Grützmann, Alexander Krüger, Daniela E. Aust, Pauline Wimberger, Jan Dominik Kuhlmann	4
4	Safety, tolerability and pharmacokinetic properties of the novel triazeneTriN2755 in tumour bearing dogs – a phase I study^† 2015 ·Veterinary and Comparative Oncology ·(unknown), (unknown), Ralf A. Hilger, Valeria Meier, Carla Rohrer Bley	1
5	Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma 2014 ·Cell Cycle ·Claudia Friesen, (unknown), Mareike Roscher, Iduna Fichtner, Andreas Alt, Ralf A. Hilger, Klaus‐Michael Debatin, E. Miltner	69
6	Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin. 2013 ·PubMed ·(unknown), (unknown), Ralf A. Hilger, Michael Gütschow, Ulrich Jaehde	11
7	Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer 2010 ·International Journal of Clinical Pharmacology and Therapeutics ·Dirk Strumberg, Beate Schultheis, M. E. Scheulen, Ralf A. Hilger, Juergen Krauss, Norbert Marschner, Florian Lordick, F. Bach, Dirk Reuter, Lutz Edler, (unknown)	12
8	Pharmacokinetic study of S-1 2009 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), Juergen Krauss, (unknown), (unknown), M. E. Scheulen, Dirk Strumberg, Axel‐R. Hanauske, Lukas Makris, P. Scigalla, (unknown), Ralf A. Hilger	2
9	Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial 2008 ·European Journal of Cancer ·Heike Richly, Beate Schultheis, Irenäus A. Adamietz, P. Kupsch, M. Grubert, Ralf A. Hilger, Matthias Ludwig, E. Brendel, O. Christensen, Dirk Strumberg	68
10	The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan 2005 ·Anti-Cancer Drugs ·Ada Braun, (unknown), Olaf Dirsch, Ralf A. Hilger, S. Seeber, U. Vanhoefer	25
11	Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer 2005 ·Clinical Colorectal Cancer ·P. Kupsch, Bernhard F. Henning, (unknown), Heike Richly, (unknown), Ralf A. Hilger, M. E. Scheulen, Olaf Christensen, E. Brendel, Brian Schwartz, (unknown), R. Voigtmann, S. Seeber, Dirk Strumberg	99
12	Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications 2004 ·Bone Marrow Transplantation ·Dietrich W. Beelen, Rudolf Trenschel, J. Casper, Mathias Freund, Ralf A. Hilger, M. E. Scheulen, Nadežda Basara, A. A. Fauser, Bernd Hertenstein, (unknown), Joachim Baumgart, Uwe Pichlmeier, J. Hahn, Ernst Holler	84
13	Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation 2004 ·International Journal of Clinical Pharmacology and Therapeutics ·Ralf A. Hilger, Joachim Baumgart, M. E. Scheulen, Rudolf Trenschel, Dirk Strumberg, S. Seeber, Dietrich W. Beelen	5
14	Curative and palliative aspects of regional chemotherapy in combination with surgery 2003 ·Supportive Care in Cancer ·(unknown), Ralf A. Hilger	17
15	Novel antitumoral compound isolated from Clusia rosea 2003 ·International Journal of Clinical Pharmacology and Therapeutics ·David Díaz-Carballo, S. Seeber, Dirk Strumberg, Ralf A. Hilger	30
16	Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma 2002 ·Urological Research ·Ch. Fleck, Ralf A. Hilger, (unknown), E. Karge, (unknown), (unknown), J. Schubert	12
17	High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer 2001 ·Journal of Cancer Research and Clinical Oncology ·Peter Bojko, M. E. Scheulen, Ralf A. Hilger, C. Oberhoff, Adolf E. Schindler, S. Seeber	8
18	Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors 1998 ·Cancer Chemotherapy and Pharmacology ·Ralf A. Hilger, A. Harstrick, Wilfried Eberhardt, C. Oberhoff, (unknown), Joachim Baumgart, S. Seeber, M. E. Scheulen	55
19	Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. 1997 ·PubMed ·U. Vanhoefer, Wieland Voigt, Ralf A. Hilger, Mingzhu Yin, A. Harstrick, S. Seeber, Y M Rustum	5
20	Dual Effect of Ammonium Persulfate on the Generation of Leukotrienes from Human Neutrophil Granulocytes 1996 ·International Archives of Allergy and Immunology ·Manfred Köller, Ralf A. Hilger, Wolfgang König	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact